Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 16.
doi: 10.1038/s41418-025-01558-9. Online ahead of print.

A positive feedback loop between SERPINH1 and MMP-9/TGF-β1 promotes lung adenocarcinoma progression

Affiliations

A positive feedback loop between SERPINH1 and MMP-9/TGF-β1 promotes lung adenocarcinoma progression

Yang Zhou et al. Cell Death Differ. .

Abstract

Lung adenocarcinoma (LUAD), the most predominant subtype of lung cancer, is a leading cause of cancer-related death worldwide. However, its underlying molecular mechanisms remain poorly understood. In this study, we identified that SERPINH1, a member of the serine protease inhibitor (serpin) superfamily, is upregulated in LUAD tissues and cells. Furthermore, high expression of SERPINH1 is associated with poor prognosis in patients. Functional experiments revealed that overexpression of SERPINH1 promotes the proliferation, invasion, and migration of LUAD cells. Further investigation showed that MMP-9 is a novel binding partner of SERPINH1. SERPINH1 enhances the protein levels of MMP-9 by inhibiting its ubiquitination, which in turn promotes the activation and secretion of extracellular TGF-β1, leading to the activation of cancer-associated fibroblasts (CAFs). Additionally, the sustained activation of TGF-β signaling further enhances the transcription of SERPINH1, establishing a positive feedback loop between SERPINH1 and TGF-β1. Taken together, our findings suggest that the SERPINH1/TGF-β1 positive feedback loop plays a crucial role in the onset and metastasis of LUAD. SERPINH1 may serve as a potential prognostic and therapeutic target in LUAD.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The collection and use of human tissue samples were approved by the Ethics Committee of Harbin Medical University Cancer Hospital, and informed consent was obtained from all patients prior to participation. All animal experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Ethics Committee of Harbin Medical University.

Similar articles

References

    1. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535–54. - PubMed
    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. - PubMed
    1. Seguin L, Durandy M, Feral CC. Lung adenocarcinoma tumor origin: a guide for personalized medicine. Cancers (Basel). 2022;14:1759. - PubMed
    1. Ma L, Xue X, Zhang X, Yu K, Xu X, Tian X, et al. The essential roles of m(6)A RNA modification to stimulate ENO1-dependent glycolysis and tumorigenesis in lung adenocarcinoma. J Exp Clin Cancer Res. 2022;41:36. - PubMed - PMC
    1. Bai Q, Wang J, Zhou X. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies. Cancer Treat Rev. 2023;120:102605. - PubMed

LinkOut - more resources